Prevalence and Burden of Headaches as Assessed by the Health Family Program

$48.00 plus tax (Refund Policy)

Download / Buy Article:

Abstract:

Background.— Migraine is comorbid to depression and widespread chronic pain (WCP), but the influence of these conditions on the health‐related quality of life (HRQoL) of individuals with episodic (EM) and chronic migraine (CM) is poorly understood.

Objective.— To assess the prevalence of depressive symptoms and WCP in individuals with EM and CM, as well as to estimate the joint impact of these conditions on the HRQoL of these individuals.

Methods.— All women aged 18 to 65 years with a first diagnosis of EM or CM from September of 2006 to September of 2008 seen in an outpatient headache service were invited to participate. They were asked to attend a separate appointment in the service and to bring another woman of similar age that also agreed to participate. Depressive symptoms were assessed using the Beck Depression Inventory. Questions about WCP followed the protocol of the American College of Rheumatology. HRQoL was assessed using the Medical Outcome Study Short‐Form 36‐item Survey (SF‐36). Multivariate analysis modeled HRQoL as a function of headache status, depressive symptoms, and pain using quantile regression.

Results.— Sample consisted of 179 women, 53 in the EM group, 37 in the CM group, and 89 in control group. Groups did not differ by demographics. Mean scores of SF‐36 were 53.6 (standard deviation [SD] = 23.5) for EM, 44.2 (SD = 18.5) for CM, and 61.8 (SD = 21.5) for controls. In multivariate analysis, SF‐36 scores were predicted by a CM status (P = .02; −10.05 [95% confidence interval −18.52; −1.58]) and by a Beck Depression Inventory score (P < .01; −1.27 [95% confidence interval −1.55; −0.99]). The influence of WCP in the SF‐36 scores approached significance (P = .08; −0.78 [95% −1.64; 0.88]). Age did not contribute to the model.

(Headache 2012;52:483‐490)

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1526-4610.2012.02090.x

Affiliations: 1: From the Headache Clinic, UFMG, Belo Horizonte, Brazil (A.A. Silva Junior, R.S. Gomez); Merck Research Laboratories, Whitehouse Station, NJ, USA (M. Bigal, A.L. Teixeira); Internal Medicine, UFMG, Belo Horizonte, Brazil (L.P.B. Vasconcelos); Medicine, UNIFENAS, Belo Horizonte, Brazil (J. Rodrigues); Neurology, Universidade Federal Fluminense, Rio de Janeiro, Brazil (A.V. Krymchantowski); Headache Clinic, Fluminense Federal University, University Hospital, Rio de Janeiro, Brazil (P. Moreira Filho); Laboratory of Immunopharmacology, UFMG, Belo Horizonte, Brazil (A.L. Teixeira). 2: From the Headache Clinic, UFMG, Belo Horizonte, Brazil (A.A. Silva Junior, R.S. Gomez); Merck Research Laboratories, Whitehouse Station, NJ, USA (M. Bigal, A.L. Teixeira); Internal Medicine, UFMG, Belo Horizonte, Brazil (L.P.B. Vasconcelos); Medicine, UNIFENAS, Belo Horizonte, Brazil (J. Rodrigues); Neurology, Universidade Federal Fluminense, Rio de Janeiro, Brazil (A.V. Krymchantowski); Headache Clinic, Fluminense Federal University, University Hospital, Rio de Janeiro, Brazil (P. Moreira Filho); Laboratory of Immunopharmacology, UFMG, Belo Horizonte, Brazil (A.L. Teixeira).

Publication date: March 1, 2012

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more